Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy

Area of Science:

• Cardiovascular Medicine
• Genetics
• Molecular Biology

Background:

• Cardiac involvement is prevalent in muscular dystrophies, manifesting as heart failure or arrhythmia.
• Traditional treatments for dystrophic cardiomyopathy focus on symptom management.
• Gene therapy presents a novel therapeutic avenue by targeting disease-causing genes and pathogenic mechanisms.

Purpose of the Study:

• To review recent advancements in gene therapy for dystrophic cardiomyopathy.
• To highlight Duchenne cardiomyopathy as a primary focus of current gene therapy research.
• To discuss the gene therapy landscape for various muscular dystrophies.

Main Methods:

• Focus on adeno-associated virus (AAV)-mediated gene therapy approaches.
• Review of preclinical studies in rodent models.
• Examination of gene therapy status for limb-girdle, congenital, and myotonic dystrophies.

Main Results:

• AAV-mediated gene therapy has demonstrated significant improvements in rodent models of Duchenne and limb-girdle muscular dystrophies.
• Preclinical research has addressed fundamental questions regarding gene therapy efficacy and safety.
• Gene therapy approaches aim to replace/repair mutated genes or modulate pathogenic processes.

Conclusions:

• Gene therapy for dystrophic cardiomyopathy is progressing steadily.
• Successful preclinical outcomes in animal models are crucial for advancing to human clinical trials.
• Further validation in large animal models is necessary before human trials.